Vystar Business Summary

Vystar Corp (VYST) operates as a diversified innovation company that generates revenue through a hybrid model of direct product sales and intellectual property licensing. The company’s primary business segments include Vytex, a multi-patented technology that removes antigenic proteins from natural rubber latex for use in bedding and medical applications; RxAir, a line of FDA-cleared Class II UV-C air purification systems; and Fluid Energy Conversion (FEC), which utilizes patented sound-energy technology (the Hughes Reactor) for advanced water filtration and pathogen destruction. Most recently, Vystar has expanded into the Web3 space through a strategic equity stake in GoPaid.com, focusing on the tokenization and monetization of high-value collectibles and memorabilia. The company competes directly with Ansell in the specialized latex market and with Molekule and Blueair in the high-end air purification sector, positioning itself as a niche IP-driven player focused on eco-friendly and medical-grade technological solutions. Vystar’s leadership is currently headed by Jamie Rotman, who serves as CEO, CFO, and President; she brings a background in marketing and management with an MBA from Clark University and prior experience as the company’s consulting controller. The Board of Directors is chaired by Joseph Allegra, Ph.D., an experienced healthcare investment advisor and instructor of epidemiology. Other key board members include Dr. Byron Novosad, a periodontist with extensive medical industry experience, and Dr. Bryan Stone, the Chairman of Medicine at Desert Regional Medical Center, who provides critical clinical oversight for the company’s healthcare-related product development. This leadership team is currently focused on navigating a strategic pivot toward high-tech filtration and digital asset monetization to stabilize the company’s financial position.